Biosimilars Market
  • Published Date: Aug-2021
  • |
  • 180 Pages
  • |
  • Report ID: HE0105

Biosimilars Market

The Biosimilars Market is expected to grow from USD 11.47 billion in 2019 to USD 98.27 billion by 2026 at a CAGR of 35.9% from 2020 to 2026.

  • Report Description
  • Table of Content
  • Segmentation
  • Companies
  • News

The biosimilars market is composed to experience rewarding development over the estimated period. As per a recent article, biosimilars are projected to play a significant role in attracting the public health issue by addressing the customer needs. The growing frequency of chronic diseases across the world, especially in developing regions due to an increase in sedentary lifestyle and increasing habit of fast food consumption will result in a rising number of people suffering from such diseases. Later, the prevalence rate in advanced as well as in certain areas in developing countries will augment the demand and adoption rate of biosimilar drugs, fueling the business growth. Innovations in monoclonal antibodies are anticipated in the biosimilars market landscape in the near future. Healthcare companies are increasing their efficiency in hybridoma-based technology to develop upgraded mAbs with the support of genetic engineering. The global market is segregated on the basis of Applications as Oncology, Chronic and autoimmune disorders, Growth hormonal deficiency, Blood disorders, and Others. Based on Product Class the global market is segmented in Immunomodulators, Anti-inflammatory Agents, Others, Recombinant Hormones, and Monoclonal Antibodies.

The global Biosimilars market report provides geographical analysis covering regions, such as Europe, North America, Asia Pacific, and the Rest of The World. The market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

Samsung Bioepis Co. Ltd, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, LG Life Sciences, Pfizer Inc, Eli Lilly and Company, Celltrion Healthcare, Mylan NV, Novartis AG, and others are among the major players in the global market. The companies studied in terms of product strategy and various n several growths and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.

The global Biosimilars market has been segmented as below:

By Applications

  • Oncology
  • Chronic and autoimmune disorders
  • Growth hormonal deficiency
  • Blood disorders
  • Others

By Product Class

  • Immunomodulators
  • Anti-inflammatory Agents
  • Others
  • Recombinant Hormones
  • Monoclonal Antibodies

By Region

  • Europe
  • North America
  • Asia Pacific
  • Rest of The World

By Company

  • Samsung Bioepis Co. Ltd
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd
  • Intas Pharmaceuticals Ltd
  • LG Life Sciences
  • Pfizer Inc
  • Eli Lilly and Company
  • Celltrion Healthcare
  • Mylan NV
  • Novartis AG

The report covers the below scope:

  • Global market sizes from 2020 to 2026, along with CAGR for 2020-2026
  • Market size comparison for 2020 vs 2026, with actual data for 2020, estimates for 2021, and forecast from 2022 to 2026
  • Global market trends, covering a comprehensive range of consumer trends & manufacturer trends
  • Value chain analysis covering participants from raw material suppliers to the downstream buyer in the global market
  • Major market opportunities and challenges in the forecast timeframe to be focused
  • Competitive landscape with analysis of competition pattern, portfolio comparisons, development trends, and strategic management
  • Comprehensive company profiles of the key industry players

The years considered for the study are as follows:

  • Base year - 2020
  • Estimated year - 2021
  • Projected year - 2022
  • Forecast period - 2022 to 2026

Report Scope:

The global market report scope includes a detailed study covering underlying factors influencing the industry trends. The report covers the analysis of regional and country-level market dynamics. The scope also covers a competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes a detailed competitive outlook covering market shares and profiles key participants in the global market share. Major industry players with significant revenue share include Samsung Bioepis Co. Ltd, Stada Arzneimittel AG, Teva Pharmaceutical Industries Ltd, Intas Pharmaceuticals Ltd, LG Life Sciences, Pfizer Inc, Eli Lilly and Company, Celltrion Healthcare, Mylan NV, Novartis AG, and others.

Why Buy this Report:

  • Gain detailed insights on the Biosimilars industry trends
  • Find a complete analysis of the market status
  • Identify the market opportunities and growth segments
  • Analyze competitive dynamics by evaluating business segments & product portfolios
  • Facilitate strategy planning and industry dynamics to enhance decision making

Target Audience:

The report targeted the existing players in the industry is as follows:

  • Market Manufacturers/Service Providers
  • Market Wholesale/Traders
  • Investment and Financial Institutions

Free and Paid Customization based on the requirement

Report Content

  1. Introduction

            1.1 Key Insights

            1.2 Report Overview

            1.3 Markets Covered

            1.4 Stakeholders

  1. Research Methodology

            2.1 Research Scope

            2.2 Market Research Process

            2.3 Research Data Analysis

                        2.4.1 Secondary Research

                        2.4.2 Primary Research

                        2.4.3 Models for Estimation

            2.5 Market Size Estimation

                        2.5.1 Bottom-Up Approach - Segmental Market Analysis

                        2.5.2 Top-Down Approach - Parent Market Analysis

  1. Executive Summary
  2. Market Overview

            4.1 Introduction

                        4.2.1 Drivers

                        4.2.2 Restraints

                        4.2.3 Opportunities

                        4.2.4 Challenges

            4.2 Porter's Five Force Analysis

  1. Biosimilars Market, By Applications

            5.1 Introduction

            5.2 Oncology

                        5.2.1 Market Overview

                        5.2.2 Market Size and Forecast

            5.3 Chronic and autoimmune disorders

                        5.3.1 Market Overview

                        5.3.2 Market Size and Forecast

            5.4 Growth hormonal deficiency

                        5.4.1 Market Overview

                        5.4.2 Market Size and Forecast

            5.5 Blood disorders

                        5.5.1 Market Overview

                        5.5.2 Market Size and Forecast

            5.6 Others

                        5.6.1 Market Overview

                        5.6.2 Market Size and Forecast

  1. Biosimilars Market, By Product Class

            6.1 Introduction

            6.2 Immunomodulators

                        6.2.1 Market Overview

                        6.2.2 Market Size and Forecast

            6.3 Anti-inflammatory Agents

                        6.3.1 Market Overview

                        6.3.2 Market Size and Forecast

            6.4 Others

                        6.4.1 Market Overview

                        6.4.2 Market Size and Forecast

            6.5 Recombinant Hormones

                        6.5.1 Market Overview

                        6.5.2 Market Size and Forecast

            6.6 Monoclonal Antibodies

                        6.6.1 Market Overview

                        6.6.2 Market Size and Forecast

  1. Biosimilars Market, By Geography

            7.1 Introduction

            7.2 Europe

                        7.2.1 Europe Market, By Applications

                        7.2.2 Europe Market, By Product Class

            7.3 North America

                        7.3.1 North America Market, By Applications

                        7.3.2 North America Market, By Product Class

            7.4 Asia Pacific

                        7.4.1 Asia Pacific Market, By Applications

                        7.4.2 Asia Pacific Market, By Product Class

            7.5 Rest of The World

                        7.5.1 Rest of The World Market, By Applications

                        7.5.2 Rest of The World Market, By Product Class

  1. Competitive Insights

            8.1 Key Insights

            8.2 Company Market Share Analysis

            8.3 Strategic Outlook

                        8.3.1 Mergers & Acquisitions

                        8.3.2 New Product Development

                        8.3.3 Portfolio/Production Capacity Expansions

                        8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements

                        8.3.5 Others

  1. Company Profiles

            9.1 Samsung Bioepis Co. Ltd

                        9.1.1 Company Overview

                        9.1.2 Product/Service Landscape

                        9.1.3 Financial Overview

                        9.1.4 Recent Developments

            9.2 Stada Arzneimittel AG

                        9.2.1 Company Overview

                        9.2.2 Product/Service Landscape

                        9.2.3 Financial Overview

                        9.2.4 Recent Developments

            9.3 Teva Pharmaceutical Industries Ltd

                        9.3.1 Company Overview

                        9.3.2 Product/Service Landscape

                        9.3.3 Financial Overview

                        9.3.4 Recent Developments

            9.4 Intas Pharmaceuticals Ltd

                        9.4.1 Company Overview

                        9.4.2 Product/Service Landscape

                        9.4.3 Financial Overview

                        9.4.4 Recent Developments

            9.5 LG Life Sciences

                        9.5.1 Company Overview

                        9.5.2 Product/Service Landscape

                        9.5.3 Financial Overview

                        9.5.4 Recent Developments

            9.6 Pfizer Inc

                        9.6.1 Company Overview

                        9.6.2 Product/Service Landscape

                        9.6.3 Financial Overview

                        9.6.4 Recent Developments

            9.7 Eli Lilly and Company

                        9.7.1 Company Overview

                        9.7.2 Product/Service Landscape

                        9.7.3 Financial Overview

                        9.7.4 Recent Developments

            9.8 Celltrion Healthcare

                        9.8.1 Company Overview

                        9.8.2 Product/Service Landscape

                        9.8.3 Financial Overview

                        9.8.4 Recent Developments

            9.9 Mylan NV

                        9.9.1 Company Overview

                        9.9.2 Product/Service Landscape

                        9.9.3 Financial Overview

                        9.9.4 Recent Developments

            9.10 Novartis AG

                        9.10.1 Company Overview

                        9.10.2 Product/Service Landscape

                        9.10.3 Financial Overview

                        9.10.4 Recent Developments

The global Biosimilars market has been segmented as below:

By Applications

  • Oncology
  • Chronic and autoimmune disorders
  • Growth hormonal deficiency
  • Blood disorders
  • Others

By Product Class

  • Immunomodulators
  • Anti-inflammatory Agents
  • Others
  • Recombinant Hormones
  • Monoclonal Antibodies

By Region

  • Europe
  • North America
  • Asia Pacific
  • Rest of The World

By Company

  • Samsung Bioepis Co. Ltd
  • Stada Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd
  • Intas Pharmaceuticals Ltd
  • LG Life Sciences
  • Pfizer Inc
  • Eli Lilly and Company
  • Celltrion Healthcare
  • Mylan NV
  • Novartis AG

License Options

  • Single 1500 USD
  • Multiple 3000 USD